Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q1 FY23 Earnings Presentation
19 slides from Jagsonpal Pharmaceuticals's earnings presentation, December 2023
Slide 1: Jagsonpal Pharmaceuticals Limited Q1 FY23 Earning Presentation
Jagsonpal Pharmaceuticals Limited Q1 FY23 Earning Presentation
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Company Background
JAGSONPAL| Company Background
Slide 4: Company Snapshot
Company Snapshot Proven Track Record • Established in 1978, long track record of 40+ years Focus Segments • Specialize in the development & commercialisation of Gynaecology & Orthopaedic focussed products Strong Brands • 17 Brands are among the “Top 5” brands in respective molecule segments Extensiv
Slide 5: Sales Team Overview
Pan India Sales Network Sales Team Overview Field force of 900+ with specialized product experience, improving productivity Network of 18 pan-India stocking points and 1,600+ stockists Super Stockist C&FA Products available in 1,25,000+ pharmacies Depot across India Warehouse 5 5
Slide 6: Gynaecology Portfolio
Demonstrated Ability to build Leading Brands: Gynae Portfolio Molecule Brand (% of Revenue) Rank in CVM MS% Brand Value 2yr CAGR-Brand 2yr CAGR-CVM Hydroxyprogesterone Maintane Inj. #2 25% ₹ 35Cr 23% 21% (₹ 140Cr) (15%) Allyeostrenol Maintane Tabs. #1 52% ₹ 17Cr 13% 9% (₹ 33Cr) (6%) Gynaecology Port
Slide 7: Orthopaedic and Other Specialty Portfolio
Demonstrated Ability to build Leading Brands: Other Specialty Portfolio Molecule Brand (% of Revenue) Rank in CVM MS% Brand Value 2yr CAGR-Brand 2yr CAGR-CVM Indomethacin Solid Indocap SR #1 84% Rs 29Cr 11% 9% (Rs 35 Cr) (13%) Orthopaedic Nandrolone Metadec #2 22% Rs 31Cr 13% 5% (Rs 145Cr) (14%) Inf
Slide 8: Recent Developments
Recent Developments Infinity Holdings acquired 43.73% stake from the Kochhar family, becoming the largest shareholder Infinity Holdings and Kochhar family are joint promoters of the company Established new Board along with induction of eminent Independent Directors Appointed Mr. Manish Gupta as the
Slide 9: Reconstituted Board with the induction of industry leaders… (1/2)
Reconstituted Board with the induction of industry leaders… (1/2) Mr. Harsha Raghavan Mr. Debasis Nandy Non-Executive Director Independent Director Invested & successfully managed businesses Experience across domains such as M&A, across industries Investor Relations Accounts, Tax, Treasury, Es
Slide 10: … with successful track record of leading business (2/2)
… with successful track record of leading business (2/2) Ms. Pallavi Gupta Mr. Prithipal S Kochhar Independent Director Non-Executive Director Worked with MNCs, NGOs, listed & privately Founder of Naari, a company focused on held companies Woman Health Advised on areas including valuation, O
Slide 11: Q1 Performance
JAGSONPAL| Q1 Performance
Slide 12: Management Commentary
Management Commentary I am excited to take up the mantle to lead Jagsonpal, which I believe has a strong business model, a talented team, and a trusted name among the medical fraternity. Building on the momentum of last year, Jagsonpal has delivered another quarter of a strong 15% growth as per IQVI
Slide 13: Q1 Performance Review
Q1 Performance Review Business • Significant outperformance as compared to the industry (Source: IQVIA / AWACS) • Growth of 15% vis-à-vis industry growth of 7% • Improved industry ranking by 9 positions as per MAT June - 89th to 80th • Strong performance by Dydrogesterone franchise (Divatrone and Pr
Slide 14: Dydrogesterone – A New Horizon for Jagsonpal
Dydrogesterone – A New Horizon for Jagsonpal • Launch of Dydrogesterone products(DGT) at a competitive price has helped expand the market, replacing the progesterone (NMP) market • DGT market has grown 59% as against 12% for NMP (MAT June 22) • DGT sales have overtaken NMP since April’22 • Jagsonpal
Slide 15: Financial Performance
JAGSONPAL| Financial Performance
Slide 16: Profit and Loss Statement
Profit and Loss Statement All values in ₹ lakhs Q1 FY 23 Q1 FY 22 Q4 FY 22 FY 22 Particulars Remarks Unaudited Unaudited Unaudited Audited Strong growth in spite of base effect of Covid product Revenue From Operations 6,059.7 5,405.5 5,122.7 21,758.4 sales in the previous year Material Consumption -
Slide 17: Exceptional/ One-time Expenses
Exceptional/ One-time Expenses All values in ₹ lakhs Expenses Break-up Q1 FY23 Q1 FY22 Q4 FY22 FY 22 Impairment losses - Faridabad Factory 89.5 - Delhi Office 168.4 - Product Development & related Costs 254.5 512.4 Restructuring Costs (Retirement / Redundancy) 68.0 Total Exceptional Costs Reported P
Slide 18: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ lakhs th st Particulars As on 30 June As on 31 March Change Remarks Shareholders Funds 13,123 13,086 37 Tangible Assets 1,964 2,237 -273 Impairment of assets pertaining to Faridabad factory & Delhi head office, product development charges written off Intangibl
Slide 19: Thank You
JAGSONPAL| Thank You
Jagsonpal Pharmaceuticals — Q1 FY23 Earnings Presentation on 6ix